News & Analysis on Clinical Trial Services & Contract Research And Development
Pfizer may have given up on its non-injectable insulin, but researchers in the US think they may have cracked a way to deliver the hormone orally, linking it up to vitamin B12 to protect it through the digestive system.
Outsourcing-Pharma.com special focus
Inyx Pharma has been given a new lease on life after it was bought by another UK firm, bringing relief after it was dragged into administration when its US parent company Inyx Inc. ran aground financially.
Illumina has released a new microRNA (miRNA) assay for gene expression profiling at a cost that the company believes is less than half that of other commercially available systems.
Scanning probe microscope maker Veeco has seen its third quarter revenues drop 13 per cent to $97.7m (€68.7m) and plans to make 100 staff redundant as part of a restructuring drive.
Pacira Pharmaceutical's modified-release formulation of morphine has been approved for marketing in Australia by the Therapeutic Goods Administration.
Sigma-Aldrich has continued its push into siRNA delivery with the release of its N-TER nanoparticle system for hard-to-transfect cell lines.
In this week's review of activity within the preclinical research services arena, new deals have emerged involving Cato Research, Genoway, Caliper Life Sciences and Rules-Based Medicine.
Japan's Kirin Holdings, best-known in the West as a beer maker, will acquire a controlling stake in Kyowa Hakko, and thus get its hands on what Kyowa claims are 'the ultimate antibody warriors' against cancer.